In fact, OBP-702 showed stronger antitumor activity than OBP-301 even against refractory cancers such as pancreatic cancer by activation of systemic antitumor immunity, in addition to oncolytic cell death and p53-mediated cytotoxic effects [13–16]. Here, TP53 is linked to pancreatic neoplasm.